IMFINZI Emerging Drug Insight and Market Forecast - 2032

This “IMFINZI Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about IMFINZI for malignant pleural mesothelioma (MPM) in the seven major markets. A detailed picture of the IMFINZI for MPM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the IMFINZI for MPM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the IMFINZI market forecast analysis for MPM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in MPM.

Drug Summary

IMFINZI (durvalumab; MEDI4736) - a product of AstraZeneca, is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody. IMFINZI is a prescription medicine used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC), extensive-stage small cell lung cancer (ES-SCLC), and for people with previously treated, locally advanced or metastatic urothelial carcinoma (bladder cancer). IMFINZI is administered intravenously and works by blocking the interaction of PD-L1 with PD-1 and CD80. This blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses without inducing antibody-dependent cell-mediated cytotoxicity (ADCC).

PrECOG, a cancer research group, formed as a not-for-profit limited liability company in 2006 by the ECOG Research and Education Foundation, with funding from AstraZeneca, has initiated clinical trials investigating IMFINZI in the first-line treatment in advanced pleural mesothelioma patients. Currently, two clinical trials are ongoing, which are NCT02899195 (PrE0505) and NCT04334759 (DREAM3R).

PrE0505 is a single-arm, open-label Phase II study in which durvalumab is under investigation in combination with standard chemotherapy. Pemetrexed and cisplatin will be given for up to six 3-week cycles with the addition of concurrent durvalumab dosed every 3 weeks. This study is being conducted in the United States and met its primary endpoint. In addition, DREAM3R is an international, open-label, multicenter, Phase III study where patients will be randomized 2:1 to receive durvalumab with standard chemotherapy or to receive standard chemotherapy alone.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the IMFINZI description, mechanism of action, dosage and administration, research and development activities in malignant pleural mesothelioma (MPM).
• Elaborated details on IMFINZI regulatory milestones and other development activities have been provided in this report.
• The report also highlights the IMFINZI research and development activities in MPM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around IMFINZI.
• The report contains forecasted sales of IMFINZI for MPM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for MPM.
• The report also features the SWOT analysis with analyst views for IMFINZI in MPM.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IMFINZI Analytical Perspective

In-depth IMFINZI Market Assessment

This report provides a detailed market assessment of IMFINZI for malignant pleural mesothelioma (MPM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

IMFINZI Clinical Assessment

The report provides the clinical trials information of IMFINZI for MPM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for malignant pleural mesothelioma (MPM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IMFINZI dominance.
• Other emerging products for MPM are expected to give tough market competition to IMFINZI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IMFINZI in MPM.
• This in-depth analysis of the forecasted sales data of IMFINZI from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the IMFINZI in MPM.

Key Questions

• What is the product type, route of administration and mechanism of action of IMFINZI?
• What is the clinical trial status of the study related to IMFINZI in malignant pleural mesothelioma (MPM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IMFINZI development?
• What are the key designations that have been granted to IMFINZI for MPM?
• What is the forecasted market scenario of IMFINZI for MPM?
• What are the forecasted sales of IMFINZI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to IMFINZI for MPM?
• Which are the late-stage emerging therapies under development for the treatment of MPM?

This product will be delivered within 2 business days.